Zoetis Inc - ZTS STOCK NEWS

Zoetis (ZTS) has received a conditional license from the USDA's Center for Veterinary Biologics for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus for use in chickens. The license was granted based on safety, purity, and reasonable efficacy expectations from serology data.

The vaccine addresses the Highly Pathogenic Avian Influenza (HPAI) crisis, which has affected over 150 million birds in the U.S. since February 2022. The conditional license is issued for a time to meet emergency conditions and can be renewed at the CVB's discretion.

This development builds on Zoetis's extensive experience in avian influenza vaccines, including their 2016 H5N1 vaccine for the USDA's National Veterinary Stockpile and their POULVAC® FLUFEND™ i AI H5N3 RG vaccine used internationally.

Zoetis (NYSE: ZTS) reported strong financial results for Q4 and full year 2024. In Q4, revenue reached $2.3 billion, up 5% year-over-year, with net income of $581 million ($1.29 per diluted share), increasing 11% and 13% respectively. The company achieved 9% organic operational growth in Q4 after accounting for recent divestitures.

For full year 2024, Zoetis posted revenue of $9.3 billion, growing 8%, with net income of $2.5 billion ($5.47 per diluted share), up 6% and 8% respectively. The company delivered 11% operational growth in revenue and 15% operational growth in adjusted net income.

Looking ahead to 2025, Zoetis projects revenue between $9.225-$9.375 billion, with expected organic operational growth of 6-8%. The company forecasts diluted EPS of $5.70-$5.80 on a reported basis, or $6.00-$6.10 on an adjusted basis.

The Zoetis (NYSE:ZTS) Board of Directors has announced a quarterly dividend of $0.50 per share for the second quarter of 2025. The dividend will be distributed on June 3, 2025, to shareholders of record as of the close of business on April 21, 2025.

Zoetis announced an updated U.S. label for Librela® (bedinvetmab injection), their once-monthly injectable treatment for canine osteoarthritis (OA) pain. The label update follows post-approval experience since the product's U.S. launch in October 2023, which has treated over one million dogs domestically.

The company maintains confidence in Librela's safety and effectiveness, noting that globally, with nearly 25 million doses distributed, adverse events remain rare - less than 10 occurrences per 10,000 treated animals. The product has been improving dogs' lives in Europe for four years.

Zoetis will immediately implement the updated label and Client Information Sheet, making them available on their website and to veterinarians. The company has conducted over 1,000 medical education webinars and provides extensive resources to support veterinarians in treating OA in dogs.

Zoetis Inc. (NYSE:ZTS) has announced a webcast and conference call scheduled for February 13, 2025, at 8:30 a.m. ET. During the event, CEO Kristin Peck and CFO Wetteny Joseph will present the company's fourth quarter and full year 2024 financial results and address questions from financial analysts. The public and investors can access the live webcast through the company's investor relations website. Pre-registration information is currently available, and a replay will be accessible on the same day.

Zoetis Inc. (NYSE:ZTS) has announced a 16% increase in its quarterly dividend payment for the first quarter of 2025. The new dividend of $0.50 per share will be paid on March 4, 2025, to shareholders of record as of January 21, 2025. CFO Wetteny Joseph attributed the increase to the company's strong performance, driven by their diverse, science-driven portfolio and differentiated execution, reaffirming their commitment to returning excess capital to shareholders.

Zoetis (NYSE:ZTS) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference scheduled for Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and engage with analysts during a Q&A session at 11:30 a.m. ET. The event will feature a live audio webcast accessible through the company's investor relations website, with a replay available afterward.

Zoetis (NYSE:ZTS) has announced major leadership changes, including the appointment of Jamie Brannan as Chief Commercial Officer in a newly created role overseeing all commercial markets globally. The restructuring aims to accelerate long-term growth and optimize global operations. Additional changes include Wafaa Mamilli's planned departure in early 2025, with Keith Sarbaugh promoted to EVP and Chief Digital & Technology Officer. Ester Banque will transition out of her role as EVP and President of U.S. Operations, with Jared Shriver promoted to President, U.S. Operations.

Zoetis (NYSE:ZTS) has announced its participation in the Jefferies London Healthcare Conference scheduled for Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and engage with analysts at 3:00 p.m. GMT. The session will be accessible through a live audio webcast on the company's investor relations website, with a replay available afterward.